Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

171.36 USD -11.49 (-6.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 640,153
Open 183.57
Bid (Size) 170.00 (1)
Ask (Size) 188.88 (1)
Prev. Close 182.85
Today's Range 170.25 - 185.54
52wk Range 121.97 - 212.00
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has ranked first in Boston Globe’s 2021 Top Places to Work in the “Largest Employer” category.... 
From Business Wire News Releases
Alnylam to Webcast Presentations at Upcoming Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually: 
From Business Wire News Releases

Performance

YTD
+33.77%
+33.77%
1 Month
+2.21%
+2.21%
3 Month
-14.40%
-14.40%
6 Month
+16.34%
+16.34%
1 Year
+32.35%
+32.35%

More News

Read More
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
From Business Wire News Releases
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
From Business Wire News Releases
Alnylam to Webcast Virtual R&D Day
From Business Wire News Releases
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
From Business Wire News Releases
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Business Wire News Releases
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
From Business Wire News Releases
Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock
Tags Health Care Biotech Benzinga
From Benzinga
Expert Ratings For Alnylam Pharmaceuticals
Tags BZI/AAR Market News ALNY
From Benzinga
Why Arbutus Biopharma Is Rocketing Higher Today
Tags MRNA ALNY Market News
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.